Standout Papers

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. 1997 2026 2006 2016 523
  1. Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. (1997)
    W ten Bokkel Huinink, Martin Gore et al. Journal of Clinical Oncology

Immediate Impact

1 by Nobel laureates 15 from Science/Nature 57 standout
Sub-graph 1 of 22

Citing Papers

Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
2023 Standout
End-Point Binding Free Energy Calculation with MM/PBSA and MM/GBSA: Strategies and Applications in Drug Design
2019 Standout
1 intermediate paper

Works of I Hudson being referenced

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer.
1997 Standout

Author Peers

Author Last Decade Papers Cites
I Hudson 683 658 555 649 28 1.7k
R N Hoover 504 350 405 152 23 1.7k
Jane C. Schroeder 779 549 246 234 52 2.2k
Lynn P. Parker 255 294 365 656 36 1.5k
E. Conti 546 208 275 195 49 1.6k
W P Tong 1131 504 338 149 31 1.8k
Ping Wang 368 687 380 118 36 1.5k
A. H. Zwinderman 248 488 368 125 36 1.7k
Yu Liu 375 299 110 154 34 1.4k
Eleftheria Kalogera 270 230 1049 226 33 1.6k
A.T.M.G. Tiebosch 623 397 578 78 53 2.2k

All Works

Loading papers...

Rankless by CCL
2026